Pembrolizumab: observed

171 studies: patients on it are followed, or it is given outside a trial. Page 1 of 2. Open to participants first (66), then studies with results posted, then the rest; newest registration first within each.

• Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial CarcinomaRecruitingNCT07870577Report a problem
• Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in ColombiaRecruitingNCT07856212Report a problem
• Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)RecruitingNCT07855926Report a problem
• Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)Not yet recruitingNCT07828652Report a problem
• ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)Not yet recruitingNCT07661251Report a problem
• Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational StudyEnrolling by invitationNCT07633353Report a problem
• Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentNot yet recruitingNCT07545486Report a problem
• Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder CancerNot yet recruitingNCT07468838Report a problem
• International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUCNot yet recruitingNCT07420855Report a problem
• Response to Neoadjuvant Treatment in Locally Advanced Thyroid CancerRecruitingNCT07419932Report a problem
• Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)RecruitingNCT07394062Report a problem
• Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLCNot yet recruitingNCT07392073Report a problem
• Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial CarcinomaRecruitingNCT07339878Report a problem
• A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With PainRecruitingNCT07326137Report a problem
• TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune MicroenvironmentRecruitingNCT07100405Report a problem
• MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.RecruitingNCT07092670Report a problem
• Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingNCT07066917Report a problem
• Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenRecruitingNCT07061379Report a problem
• Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07054086Report a problem
• Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung CancerNot yet recruitingNCT07035860Report a problem
• Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
• Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in ChildrenNot yet recruitingNCT07020052Report a problem
• GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）RecruitingNCT06988592Report a problem
• Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.Not yet recruitingNCT06797479Report a problem
• Observational Study of Patients with Advanced Melanoma (skin Cancer) to Assess If IOpener®-melanoma Test Can Predict Response to Immunotherapy.RecruitingNCT06784778Report a problem
• Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life ContextRecruitingNCT06781450Report a problem
• Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .RecruitingNCT06734533Report a problem
• Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT06733987Report a problem
• The Immune Assessment of PD-1 Antibody Therapy in TumorRecruitingNCT06693440Report a problem
• Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial CarcinomaRecruitingNCT06657157Report a problem
• Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus PembrolizumabRecruitingNCT06648057Report a problem
• Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma ManagementRecruitingNCT06627595Report a problem
• Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic NeviRecruitingNCT06599619Report a problem
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerRecruitingNCT06532149Report a problem
• Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and ImmunotherapyNot yet recruitingNCT06418139Report a problem
• Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)RecruitingNCT06353854Report a problem
• Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 InhibitorRecruitingNCT06310915Report a problem
• A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.RecruitingNCT06205732Report a problem
• PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLCRecruitingNCT06195527Report a problem
• DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT06194695Report a problem
• Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric AssessmentsRecruitingNCT06138561Report a problem
• Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICIRecruitingNCT06100796Report a problem
• Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)RecruitingNCT05996263Report a problem
• Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics PlatformRecruitingNCT05916755Report a problem
• Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerRecruitingNCT05910710Report a problem
• Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With PembrolizumabRecruitingNCT05877859Report a problem
• Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT05717738Report a problem
• Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT05713994Report a problem
• Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaRecruitingNCT05573282Report a problem
• Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected MelanomaRecruitingNCT05527795Report a problem
• Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLCRecruitingNCT05418660Report a problem
• ARON-2 Study-Multicentric International Retrospective StudyRecruitingNCT05290038Report a problem
• International Multicentric Study ARON-1RecruitingNCT05287464Report a problem
• Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT05260606Report a problem
• Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingNCT05139706Report a problem
• Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLCRecruitingNCT04886401Report a problem
• A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint BlockadeRecruitingNCT04807127Report a problem
• A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLCRecruitingNCT04807114Report a problem
• Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational StudyRecruitingNCT04680598Report a problem
• Immunotherapy in Lung Cancer: Treatment After IO Cessation.RecruitingNCT04465942Report a problem
• Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLCRecruitingNCT04324151Report a problem
• JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingNCT04294771Report a problem
• Development and Analysis of a Stool Bank for Cancer PatientsEnrolling by invitationNCT04291755Report a problem
• KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RecruitingNCT04165798Report a problem
• Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingNCT04107168Report a problem
• Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced MelanomaRecruitingNCT02673970Report a problem
• A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedNCT05834348Results postedReport a problem
• Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in MelanomaCompletedNCT05105100Results postedReport a problem
• To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell CarcinomaCompletedNCT04682587Results postedReport a problem
• Imaging FDG Flare in MelanomaCompletedNCT02791594Results postedReport a problem
• Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell CarcinomaCompletedNCT07902544Report a problem
• Emulation of the KEYNOTE177 Trial Using Specialty Oncology Electronic Health Records DatabasesActive, not recruitingNCT07861347Report a problem
• First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainActive, not recruitingNCT07852884Report a problem
• Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell CarcinomaCompletedNCT07827482Report a problem
• Pharmacokinetic Study of Therapeutic Plasma ExchangeWithdrawnNCT07756242Report a problem
• Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaActive, not recruitingNCT07718139Report a problem
• A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruitingNCT07645209Report a problem
• The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort StudyCompletedNCT07639294Report a problem
• Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records DatabasesActive, not recruitingNCT07485179Report a problem
• Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center AnalysisCompletedNCT07256184Report a problem
• Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.CompletedNCT07207928Report a problem
• Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI StudyCompletedNCT07192926Report a problem
• Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung CarcinomaCompletedNCT07111104Report a problem
• Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1CompletedNCT07036016Report a problem
• Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and CetuximabCompletedNCT07015333Report a problem
• Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaCompletedNCT06771674Report a problem
• HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCCActive, not recruitingNCT06632106Report a problem
• CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]CompletedNCT06607393Report a problem
• Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based StudyCompletedNCT06599463Report a problem
• CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]CompletedNCT06585189Report a problem
• ICIs With and Without MWA in Advanced Hepatocellular CarcinomaCompletedNCT06581497Report a problem
• Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsCompletedNCT06345183Report a problem
• Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)WithdrawnNCT06283238Report a problem
• Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138Report a problem
• Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic CancerCompletedNCT06195254Report a problem
• Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint InhibitorsCompletedNCT06119347Report a problem
• CX3CR1+T Cell Predict Immunotherapy EfficacyCompletedNCT06054152Report a problem
• Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRCCompletedNCT06031376Report a problem
• Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal CancerCompletedNCT06011330Report a problem
• A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)Active, not recruitingNCT05993234Report a problem

← Pembrolizumab